The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Antibody profiles for the diagnosis of antiphospholipid syndrome
Abstract
Summary: Among the so called‘antiphospholipid antibodies’, the presence of Lupus Anticoagulant (LA) is associated with thrombosis-related events and defines the antiphospholipid syndrome. The role of anti-cardiolipin (aCL) antibodies and anti-human β2-glycoprotein I (aβ2GPI) antibodies is less striking. Since the problem of standardization for these tests is far from resolved, we evaluated whether the combination of results (antiphospholipid laboratory profiles) could help to better classify these patients. Over a 6-year period, 618 consecutive subjects (55% of whom had previous documented thrombosis-related events) were referred to our clinic for Antiphospholipid antibody detection. LA was detected according to internationally accepted recommendations. ACL and aβ2GPI antibodies were detected by Enzyme-Linked-Immunosorbent Assay (ELISA). Patients’ records were reviewed for the presence of previous thromboembolic events or obstetric complications according to Sapporo’s clinical criteria for the diagnosis of antiphospholipid syndrome (APS) and each patient underwent a physical examination. When individual tests were considered in a multivariate analysis which took into account age, gender, the presence of SLE or other autoimmune diseases and established risk factors for venous and arterial thromboembolism, LA (Odds Ratio 4.4, Confidence Interval 1.5–13.3) and aβ2GPI antibodies (Odds Ratio 2.9, Confidence Interval 1.1–7.5) but not aCL antibodies (Odds Ratio 1.2, Confidence Interval 0.5–2.7) were found to be independent risk factors for thrombosis-related events. When antiphospholipid antibody profiles instead of individual test positivity were analyzed in the above mentioned model, triple positivity resulted a strong independent risk factor (Odds Ratio 33.3, Confidence Interval 7.0–157.6), retaining its significance when the association with venous or arterial thromboembolism was considered. Double positivity with negative LA was close to significance for thrombosis-related events (Odds Ratio 2.2, Confidence Interval1.0–5.2, p=0.056) and highly significant risk factor for obstetric complications (Odds Ratio 10.8, Confidence Interval 2.9–40.8). Other combinations did not reach statistical significance. The mean level of IgG aβ2GPI antibodies was statistically higher in triple positive profile and might account for positive LA. As compared to a single test, the analysis of a complete antiphospholipid antibody profile can better determine patients at risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor
Galli, M., Barbui, T., Comfurius, P., Maassen, C., Hemker, H. C., Zwaal, R. F. A., Bevers, E. M., de Baets, M. H., & van Breda-Vriesman, P. J. C. (1990) · The Lancet · doi:10.1016/0140-6736(90)91374-j · Cited by 1,270
Brandt, J. T., Triplett, D. A., Alving, B. M., & Scharrer, I. (1995) · PubMed · Cited by 1,164
Galli, M., Luciani, D., Bertolini, G., & Barbui, T. (2003) · Blood · doi:10.1182/blood-2002-02-0441 · Cited by 972
Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease
Matsuura, E., Igarashi, Y., Fujimoto, M., Ichikawa, K., & Koike, T. (1990) · The Lancet · doi:10.1016/0140-6736(90)91697-9 · Cited by 720
Bevers, E. M., Galli, M., Barbui, T., Comfurius, P., & Zwaal, R. F. A. (1991) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646476 · Cited by 576
Matsuura, E., Igarashi, Y., Yasuda, T., Triplett, D. A., & Koike, T. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.2.457 · Cited by 529
Finazzi, G., Brancaccio, V., Moia, M., Ciavarella, N., Mazzucconi, M. G., Schinco, P., Ruggeri, M., Pogliani, E. M., Gamba, G., Rossi, E., et al. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00060-5 · Cited by 427
Galli, M., Luciani, D., Bertolini, G., & Barbui, T. (2003) · Blood · doi:10.1182/blood-2002-11-3334 · Cited by 413
Roubey, R. A. S., Eisenberg, R. A., Harper, M. F., & Winfield, J. B. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.2.954 · Cited by 329
OutiVaarala, MattiMänttäri, VesaManninen, LeenaTenkanen, MarjaPuurunen, KimmoAho, & TimoPalosuo (1995) · Circulation · Cited by 305
Immunology of the antiphospholipid antibody syndrome
Roubey, R. A. S. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390903 · Cited by 302
Wahl, D., Guillemin, F., de Maistre, E., Perret, C., Lecompte, T., & Thibaut, G. (1997) · Lupus · doi:10.1177/096120339700600510 · Cited by 285
Viard, J.-P., Amoura, Z., & Bach, J.-F. (1992) · The American Journal of Medicine · doi:10.1016/0002-9343(92)90049-h · Cited by 264
Cabiedes, J., Cabral, A. R., & Alarcón-Segovia, D. (1995) · PubMed · Cited by 222
Blank, M., Faden, D., Tincani, A., Kopolovic, J., Goldberg, I., Gilburd, B., Allegri, F., Balestrieri, G., Valesini, G., & Shoenfeld, Y. (1994) · Journal of Autoimmunity · doi:10.1006/jaut.1994.1032 · Cited by 190
Antiprothrombin Antibodies: Detection and Clinical Significance in the Antiphospholipid Syndrome
Galli, M., & Barbui, T. (1999) · Blood · doi:10.1182/blood.v93.7.2149 · Cited by 180
Anti β2 glycoprotein I antibodies: detection and association with thrombosis
Martinuzzo, M. E., Forastiero, R. R., & Carreras, L. O. (1995) · British Journal of Haematology · doi:10.1111/j.1365-2141.1995.tb03317.x · Cited by 163
Pengo, V, Biasiolo, A., Brocco, T., Tonetto, S., & Ruffatti, A. (1996) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650355 · Cited by 159
Self-citationAnti-beta 2-glycoprotein I antibodies: a marker of antiphospholipid syndrome?
Balestrieri, G., Tincani, A., Spatola, L., Allegri, F., Prati, E., Cattaneo, R., Valesini, G., Papa, N. D., & Meroni, P. L. (1995) · Lupus · doi:10.1177/096120339500400208 · Cited by 147
Pengo, V., Biasiolo, A., & Fior, M. G. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1653721 · Cited by 126
Self-citationReber, G., Schousboe, I., Tincani, A., Sanmarco, M., Kveder, T., de Moerloose, P., Boffa, M., & Arvieux, J. (2002) · PubMed · Cited by 119
Jennings, I., Kitchen, S., Woods, T. A. L., Preston, F. E., & Greaves, M. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1656080 · Cited by 103
Meijer, P., Vermylen, J., & Arnout, J. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614601 · Cited by 96
Roubey, R. A. S., Maldonado, M. A., & Byrd, S. N. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390922 · Cited by 86
Biasiolo, A., Rampazzo, P., Brocco, T., & Pengo, V. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614453 · Cited by 76
Self-citationA two‐step coagulation test to identify antiβ2‐glycoprotein I lupus anticoagulants
Pengo, V., Biasiolo, A., Pegoraro, C., & Iliceto, S. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00712.x · Cited by 70
Self-citationRampazzo, P., Biasiolo, A., Garin, J., Rosato, A., Betterle, C., Ruffatti, A., & Pengo, V. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1612904 · Cited by 34
Self-citationBiasiolo, A., & Pengo, V. (1993) · Blood Coagulation & Fibrinolysis · doi:10.1097/00001721-199306000-00005 · Cited by 31
Self-citationWhich Antiphospholipid Antibodies Should Be Measured in the Antiphospholipid Syndrome?
Galli, M. (2000) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000054164 · Cited by 25
Pengo, V., Balestrieri, G., Tincani, A., Spatola, L., Biasiolo, A., & Brocco, T. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1655918 · Cited by 25
Self-citationThe Risk of Overdiagnosis of Antiphospholipid Antibody Syndrome
Biasiolo, A., & Pengo, V. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1616156 · Cited by 14
Self-citationWilson (1999) · doi:10.1002/1529-0131(199907)42:7<1309::aid-anr1>3.0.co;2-f
Cited by
Ruiz-Irastorza, G., Crowther, M., Branch, W., & Khamashta, M. A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60709-x · Cited by 831
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome
Pengo, V., Denas, G., Zoppellaro, G., Jose, S. P., Hoxha, A., Ruffatti, A., Andreoli, L., Tincani, A., Cenci, C., Prisco, D., et al. (2018) · Blood · doi:10.1182/blood-2018-04-848333 · Cited by 822
Self-citationClinical course of high‐risk patients diagnosed with antiphospholipid syndrome
PENGO, V., RUFFATTI, A., LEGNANI, C., GRESELE, P., BARCELLONA, D., ERBA, N., TESTA, S., MARONGIU, F., BISON, E., DENAS, G., et al. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03674.x · Cited by 632
Self-citationRuiz-Irastorza, G., Cuadrado, M., Ruiz-Arruza, I., Brey, R., Crowther, M., Derksen, R., Erkan, D., Krilis, S., Machin, S., Pengo, V, et al. (2011) · Lupus · doi:10.1177/0961203310395803 · Cited by 506
Self-citationPengo, V., Ruffatti, A., Legnani, C., Testa, S., Fierro, T., Marongiu, F., De Micheli, V., Gresele, P., Tonello, M., Ghirarduzzi, A., et al. (2011) · Blood · doi:10.1182/blood-2011-03-340232 · Cited by 468
Self-citation
Metadata
- Authors
- Biasiolo, A., Pegoraro, C., Cucchini, U., Noventa, F., Iliceto, S., & Pengo, V.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2005
- Volume
- 93
- Issue
- 06
- Pages
- 1147-1152
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2041919675
- Cited by
- 320
- References
- 33
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.